Avacta will be generating cash on Dox soon!15 Apr 2024 06:31
Too many newbie’s trying to sound like they have a clue in what is going on here.
Worth checking out the below to realise how close they are to getting targeted therapy approved for certain indications.
precision conjugates can get approved quicker than new drugs. This is because precision conjugates are often based on existing drugs that have already been approved for use. This means that the safety and efficacy of the drug has already been established, and the focus of the approval process can be on the new delivery system.
In addition, precision conjugates are often designed to target specific diseases or conditions. This can make them more effective than traditional drugs, which may have a broader range of side effects. As a result, precision conjugates may be approved for use in specific patient populations, which can reduce the time it takes to get them to market.
Here are some examples of precision conjugates that have been approved quicker than new drugs:
* **Brentuximab vedotin (Adcetris)**: This precision conjugate was approved by the FDA in 2011 for the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It was approved based on a clinical trial that showed that it was more effective than the standard treatment at the time.
* **Trastuzumab emtansine (Kadcyla)**: This precision conjugate was approved by the FDA in 2013 for the treatment of HER2-positive breast cancer. It was approved based on a clinical trial that showed that it was more effective than the standard treatment at the time.
* **Enfortumab vedotin (Padcev)**: This precision conjugate was approved by the FDA in 2019 for the treatment of urothelial cancer. It was approved based on a clinical trial that showed that it was more effective than the standard treatment at the time.
Overall, precision conjugates are a promising new approach to drug delivery. They have the potential to improve the efficacy and reduce the side effects of drugs, which could lead to better outcomes for patients.